^
    9ms
    🎥@MichaelGnant of @MedUni_Wien discusses late recurrences in ER-positive breast cancer at #ASCO23. Optimal treatment duration is 7-8 years, with 10 years for high-risk cases. The carryover effect brings long-lasting benefits: ➡️https://t.co/OG8RHYWG95⬅️ #BreastCancer #BCSM (@VJOncology)
    Clinical
    |
    ER (Estrogen receptor)
    |
    ER positive
    9ms
    Excellent panel discussion for Session IV on ER Positive Breast Cancer in the #HarvardBreastCancerCourse. #PabloLeone @PTarantinoMD @elmayermd @alex_toker @christinaminami @RMJesel @BeverlyMoy @drsarahsam (@DFCI_BreastOnc)
    ER (Estrogen receptor)
    |
    ER positive
    10ms
    @ASCO Educational Book provides insightful summaries with great impact on clinical practice! @ABCSGVienna President @MichaelGnant contributes with an overview – based on his ASCO talk – on managing ER-positive breast cancer and challenges of late relapse. https://t.co/mwD3euw9w2 (@ABCSGVienna)
    Clinical
    |
    ER (Estrogen receptor)
    |
    ER positive
    11ms
    Not to miss at #ASCO23: Today: Education Session Hall D1: Managing a Long and Winding Road: ER-Positive Breast Cancer Hear @MichaelGnant Editor-in-Chief of Breast Care, speak on Late Recurrences in ER-Positive Breast Cancer: What Else Can We Do? #BreastCancer @KargerPublisher (@OncoKarger)
    ER (Estrogen receptor)
    |
    ER positive
    11ms
    Identifying Patterns and Barriers in #OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive #Breastcancer : Implications for Guidance and Reimbursement https://t.co/pnK0bjZZgN @ASCO @JCOOP_ASCO @DrHBurstein @PTarantinoMD @stolaney1 (@jamecancerdoc)
    Clinical • Reimbursement • US reimbursement
    |
    ER (Estrogen receptor)
    |
    Oncotype DX Breast Recurrence Score®Test
    12ms
    @ASCO #ASCO23 #ASCODailyNews ER-Positive Breast Cancer: Assessing Late Relapse and Moving Treatment Forward https://t.co/0vIqH2EzGs (@GlopesMd)
    ER (Estrogen receptor)
    |
    ER positive
    12ms
    Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? An excellent review👇 https://t.co/WEdbZlHexv (@dr_yakupergun)
    Review
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    1year
    Household income linked to recurrence score, mortality in #ERPositiveBreastCancer Anurag K. Singh MD, @Single_Fx_Singh et al. @RoswellPark https://t.co/dEPn29yXDS @GoHealio (@RMilesMD)
    ER (Estrogen receptor)
    |
    ER positive
    1year
    WATCH: @VKaklamani, of @UTHealthSA, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer. #bcsm #oncology https://t.co/LZEgCdDY5I (@OncLive)
    ER (Estrogen receptor)
    |
    ER positive
    1year
    Goodness - if chemo benefit due to hormone effects , does this mean we could go back to ovarian ablation without chemotherapy for ER positive breast cancer ? #stgalen (@Maherjane)
    ER (Estrogen receptor)
    |
    ER positive
    1year
    High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer https://t.co/V9r165wktg (@weldeiry)
    ER (Estrogen receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    ER positive
    over1year
    Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant. #bcsm #SABCS2022 | @SABCSSanAntonio @elmayermd https://t.co/g2URYk0qxm (@CancerNetwrk)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant
    over1year
    MD Cynthia X. welcomed us this morning to discuss evolving data regarding pathologic and molecular characteristics of ER positive breast cancer at her session “Hormone receptor positive breast cancer”, Amazing information!👍🏼🩺 #CIMO2022 #BreastCancer @SABCSSanAntonio (@Dr_Ivanoncologo)
    ER (Estrogen receptor)
    |
    ER positive • HR positive
    over1year
    PD13-01 Thursday @SABCSSanAntonio Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial Presenter: @vidalmar80 (@prat_aleix)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Orserdu (elacestrant)
    over1year
    Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective s… https://t.co/QkCKhyiDYb De escalating endocrine therapy in small tumors (@FilippoMontemu1)
    Retrospective data
    |
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Q4 HER2 mutations can be acquired in ER-positive breast cancer, are actionable and can be targeted with TKIs such as neratinib #HER2low (@oreganruth)
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 mutation
    |
    Nerlynx (neratinib)
    over1year
    Another piece of the puzzle: Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer. The oral SERDs saga continues. Stay tuned https://t.co/FwLjrGwOKG (@CarmenCriscit)
    ER (Estrogen receptor)
    |
    ER positive
    |
    fulvestrant • camizestrant (AZD9833)
    over1year
    Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR) #bcsm. https://t.co/AtIDQ9WZLs (@FuenteApolo)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Excited to review the data at the upcoming meeting! Congrats to all involved. Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer | Business Wire https://t.co/Z1PhUWA5cb (@jhaveri_komal)
    Review
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    fulvestrant • camizestrant (AZD9833)
    over1year
    After a median of 50 months of follow-up, palbociclib plus adjuvant endocrine therapy did not improve invasive disease-free survival in a subgroup of patients with stage IIA estrogen receptor–positive breast cancer. #bcsm | @AngieDemichele https://t.co/1IMBl9V4sI (@CancerNetwrk)
    Clinical
    |
    ER (Estrogen receptor)
    |
    Ibrance (palbociclib)
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/VVrKh2Os2P @ClinOncNews @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@SpecialtyPharm)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    NRG Currents Newsletter Featured Trial: De-escalating Breast Radiation After Lumpectomy for Low Risk, Estrogen Receptor Positive, Breast Cancer (The DEBRA Trial/NRG-BR007). Read more: https://t.co/Sj6BDrQmpi @Dr_Julia_White @TBJulianMD (@NRGonc)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Looking forward to tonight’s discussion and review of axillary management in node-positive ER-positive breast cancer at 7pm ET. @ASBrS @DrJudyBoughey @ZAlHilliMD (@ToanNguyenMD)
    Review
    |
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/VVrKh2xp0P @ClinOncNews @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@SpecialtyPharm)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/VVrKh2wRbh @ClinOncNews @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@SpecialtyPharm)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/dQnF967v9v @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@ClinOncNews)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/dQnF967v9v @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@ClinOncNews)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/dQnF967v9v @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@ClinOncNews)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/dQnF967v9v @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@ClinOncNews)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/dQnF967v9v @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@ClinOncNews)
    ER (Estrogen receptor)
    |
    ER positive
    over1year
    Hot flashes may predict worse outcomes for ER-positive breast cancer. https://t.co/dQnF967v9v @jamecancerdoc #oncology #oncologist #cancer #breastcancer (@ClinOncNews)
    ER (Estrogen receptor)
    |
    ER positive
    almost2years
    NICE approves two treatment options for advanced breast cancer https://t.co/MraoHvwr6i Alpelisib first targeted treatment for patients with PIK3CA mutation found in 30-40% of oestrogen receptor positive HER2 negative breast cancers @DrIanWeissman @SusanChubb1 @SirGeoffPalmer (@Nigelj08223326)
    Clinical • NICE
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • ER positive + HER-2 negative
    |
    Piqray (alpelisib)
    almost2years
    WATCH: @ErikaHamilton9, of @SarahCannonDocs, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer. #bcsm https://t.co/Xb4rPjl25i (@OncLive)
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    almost2years
    As CRC is not a smoldering disease like ER positive breast cancer, most patients relapse within 3 years (nicely shown in a curve by Dan Sargent in the evidence for cure paper)-I don’t anticipate many relapses beyond year 3, but time will tell. (@doctorC369)
    Clinical
    |
    ER (Estrogen receptor)
    |
    ER positive
    almost2years
    Dr. Julia Giordano and co-authors (@OKantorMD, @DrHBurstein, @stolaney1, @TariKingMD, @DrBOvermoyer and others) shared their #ASCO22 poster titled: Is there a role for the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer? ()
    ER (Estrogen receptor)
    |
    ER-L
    |
    Oncotype DX Breast Recurrence Score®Test
    almost2years
    During #NSABP2022, Dr. Jame Abraham @jamecancerdoc discusses the NSABP B-60 study. This trial is recruiting patients with estrogen receptor positive, HER-2 negative early #breastcancer. (@NSABPFoundation)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    2years
    GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers | Communications Biology https://t.co/6mEeIN6KBE @GaiaBianco7 @john_gallon127 @Rain_Thera @MariannKruithof @DepBiomedicine @UniBasel_en @charlottekyng @DBMR_UniBe @caner_ercan @betta1009 @rdoebele (@s_piscuoglio)
    Synthetic lethality
    |
    ER (Estrogen receptor) • GATA3 (GATA binding protein 3)
    |
    ER positive
    2years
    Improving Survival in Advanced, #ERPositiveBreastCancer GN Hortobagyi MD et al. @NEJM @JWatch https://t.co/2rdiWKwz2U [subscription] #Ribociclib #Letrozole (@RMilesMD)
    ER (Estrogen receptor)
    |
    ER positive
    |
    Kisqali (ribociclib) • letrozole
    2years
    Sara Tolaney, MD, MPH, discusses the data with the oral selective estrogen receptor degrader, elacestrant, and the androgen receptor agonist, enobosarm, in estrogen receptor–positive, HER2-negative breast cancer. @stolaney1 @DanaFarber #bcsm https://t.co/tbkI8PXWlD (@OncLive)
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)
    |
    HER-2 negative
    |
    Orserdu (elacestrant) • Ostarine (enobosarm)
    2years
    Enobosarm, an investigational, nonsteroidal, selective androgen receptor agonist, could represent a new treatment approach in estrogen receptor–positive, AR-positive metastatic breast cancer @breastoncdoc @UPMCHillmanCC #bcsm https://t.co/RLFz4alDLQ (@OncLive)
    ER (Estrogen receptor) • AR (Androgen receptor)
    |
    AR positive
    |
    Ostarine (enobosarm)
    2years
    Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with ER-Positive Breast Cancer (Webinar Video Proceedings) | Research To Practice: Featuring our own ⁦@oreganruth⁩ ⁦@UR_Med⁩ ⁦⁦@WilmotCancer⁩! https://t.co/yW1GFitkBs (@DrCarlaCasulo)
    Clinical • Video
    |
    ER (Estrogen receptor)
    |
    ER positive
    over2years
    35) SO there you have it--a quick review of data from #SABCS21 on ER positive breast cancer, advanced stage. You've just earned 0.5h CE/#CME! Go to https://t.co/ml5gmGoGmq to claim it! I am @drhburstein and I hope you will FOLLOW US for more expert-authored programs! (@onc_ce)
    Review • CME
    |
    ER (Estrogen receptor)
    |
    ER positive